

Enrique Carrazana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9614147/publications.pdf>

Version: 2024-02-01

22
papers

356
citations

1040056

9
h-index

888059

17
g-index

22
all docs

22
docs citations

22
times ranked

122
citing authors

#	ARTICLE	IF	CITATIONS
1	Comment on "Intranasal midazolam versus intravenous/rectal benzodiazepines for acute seizure control in children: A systematic review and meta-analysis" Epilepsy and Behavior, 2022, 128, 108550.	1.7	7
2	Use of second doses of Valtoco [®] (diazepam nasal spray) across 24 hours after the initial dose for out-of-hospital seizure clusters: Results from a phase 3, open-label, repeat-dose safety study. Epilepsia, 2022, 63, 836-843.	5.1	13
3	Identification of risk factors and distinguishing psychogenic nonepileptic seizures from epilepsy: A retrospective case-control study. Clinical Neurology and Neurosurgery, 2022, 217, 107221.	1.4	7
4	Lack of clinically relevant differences in safety and pharmacokinetics after second-dose administration of intranasal diazepam within 4 hours for acute treatment of seizure clusters: A population analysis. Epilepsia, 2022, 63, 1714-1723.	5.1	6
5	Native Hawaiian and Other Pacific Islanders [™] Leading Risk Factors for Ischemic Stroke: A Comparative Ethnographic Study. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106433.	1.6	3
6	Safety of Diazepam Nasal Spray in Children and Adolescents With Epilepsy: Results From a Long-Term Phase 3 Safety Study. Pediatric Neurology, 2022, 132, 50-55.	2.1	12
7	Identification of associations and distinguishing moyamoya disease from ischemic strokes of other etiologies: A retrospective case-control study. Annals of Medicine and Surgery, 2022, 78, .	1.1	3
8	Quality-of-life results in adults with epilepsy using diazepam nasal spray for seizure clusters from a long-term, open-label safety study. Epilepsy and Behavior, 2022, 134, 108811.	1.7	9
9	Epilepsy in the time of COVID-19. Acta Neurologica Scandinavica, 2021, 143, 333-335.	2.1	6
10	Overcoming the challenges of developing an intranasal diazepam rescue therapy for the treatment of seizure clusters. Epilepsia, 2021, 62, 846-856.	5.1	30
11	Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study. Epilepsia, 2021, 62, 1442-1450.	5.1	13
12	Lack of observed impact of history or concomitant treatment of seasonal allergies or rhinitis on repeated doses of diazepam nasal spray administered per seizure episode in a day, safety, and tolerability: Interim results from a phase 3, open-label, 12-month repeat-dose safety study. Epilepsy and Behavior, 2021, 118, 107898.	1.7	12
13	Lack of observed tolerance to diazepam nasal spray (Valtoco [®]) after long-term rescue therapy in patients with epilepsy: Interim results from a phase 3, open-label, repeat-dose safety study. Epilepsy and Behavior, 2021, 120, 107983.	1.7	10
14	Improvement of Intranasal Drug Delivery with Intravail [®] Alkylsaccharide Excipient as a Mucosal Absorption Enhancer Aiding in the Treatment of Conditions of the Central Nervous System. Drugs in R and D, 2021, 21, 361-369.	2.2	19
15	Variables Associated with Coronavirus Disease 2019 Vaccine Hesitancy Amongst Patients with Neurological Disorders. Infectious Disease Reports, 2021, 13, 763-810.	3.1	11
16	Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy. Epilepsia, 2021, 62, 2485-2495.	5.1	47
17	Characterizing idiopathic intracranial hypertension socioeconomic disparities and clinical risk factors: A retrospective case-control study. Clinical Neurology and Neurosurgery, 2021, 208, 106894.	1.4	3
18	Recommendations for development of acute seizure action plans (ASAPs) from an expert panel. Epilepsy and Behavior, 2021, 123, 108264.	1.7	23

#	ARTICLE	IF	CITATIONS
19	Early impact of the COVID-19 pandemic on outpatient migraine care in Hawaii: Results of a quality improvement survey. <i>Headache</i> , 2021, 61, 149-156.	3.9	18
20	Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteers. <i>Epilepsia</i> , 2020, 61, 455-464.	5.1	47
21	Evaluation of Pharmacokinetics and Dose Proportionality of Diazepam After Intranasal Administration of NRL-1 to Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 719-727.	1.6	17
22	Pharmacokinetics and safety of VALTOCO (NRL-1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri-ictal) and nonseizure (interictal) conditions: A phase 1, open-label study. <i>Epilepsia</i> , 2020, 61, 935-943.	5.1	40